Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenia

Kyle LaHucik

Senior Reporter

Multiple biotech companies have made noise in schizophrenia R&D this year, with a landmark drug approval request and several large financings, and on Tuesday morning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenia

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Dutch-US biotech rais­es $61M to test ex-Mit­subishi Tan­abe drug for schiz­o­phre­nia

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenia